LRMR
Larimar Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website larimartx.com
- Employees(FY) 26
- ISIN US5171251003
Performance
+3.01%
1W
+38.38%
1M
+5.79%
3M
-43.27%
6M
-29.2%
YTD
-65.71%
1Y
Profile
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.
Technical Analysis of LRMR 2025-06-18
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2025-04-29 19:00
- 2025-04-04 01:12
- 2025-03-23 19:00
- 2025-03-03 03:05
- 2025-01-23 03:05
Page 1 of 1
previousnext
Disclaimer: The information provided here and on kavout.com is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout makes no recommendations regarding investment decisions based on this information. You are solely responsible for your investments. Please conduct your own research and consult qualified financial advisors before investing. Past performance does not guarantee future results.